The Fly | EVGN

Evogene

· EVGN

Dashboard

Financials

Ratios

Transcripts

Valuation

Yesterday

Evogene achieves integration of agentic systems with ChemPass AI platform

Yesterday, 8:05 AM

Over a week ago

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

EVGN

Jun 2, 7:04 AM

Evogene price target lowered by 10c at Alliance Global, here's why

May 26, 3:07 PM

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

EVGN

May 20, 7:08 AM

Evogene price target raised by 50c at Alliance Global, here's why

EVGN

Apr 13, 10:18 AM

Evogene receives Nasdaq minimum bid price notification

EVGN

Apr 2, 4:03 PM

Evogene files to sell 5.08M ordinary shares for holders

EVGN

Mar 26, 4:32 PM

Evogene price target lowered by 75c at Alliance Global, here's why

EVGN

Mar 13, 11:37 AM

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

EVGN

Mar 5, 7:03 AM

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

EVGN

Feb 17, 8:09 AM

Evogene Systasy Bioscience and LMU University announce collaboration

EVGN

Feb 11, 8:09 AM

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

Feb 10, 8:12 AM

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

EVGN

Feb 5, 5:59 AM

Biomica and Lishan Biotech sign licensing agreement for BMC128

EVGN

Feb 4, 8:04 AM

Evogene, Unravel Biosciences announce scientific collaboration

EVGN

Jan 7, 7:14 AM

Evogene appoints Nissan as VP of Business Development

EVGN

Dec 30, 7:05 AM

Evogene's Casterra and Fantini announce strategic collaboration

EVGN

Nov 11, 7:05 AM

What You Missed On Wall Street On Friday

+24

Aug 22, 4:38 PM

Nvidia reportedly stops H20 AI chip output for China: Morning Buzz

+27

Aug 22, 1:44 PM

Morning Movers: Cenovus Energy rises following deal to acquire MEG Energy

Aug 22, 8:59 AM

Evogene reports Q2 EPS (10c) vs. (5c) last year

EVGN

Aug 22, 5:52 AM

Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

EVGN

Aug 19, 7:06 AM

No more stories

Bio-Convergence Technology Platform: Evogene's unique Bio-Convergence platform integrates computational biology, AI/ML, and high-throughput experimental validation to accelerate the discovery and development of novel life science products across various industries.

Proprietary Data and AI Algorithms: The company possesses extensive proprietary biological and chemical databases, coupled with advanced machine learning algorithms, providing a powerful engine for predictive modeling and efficient identification of new targets and product candidates.

Diversified Vertical Market Strategy: Operating through specialized subsidiaries (e.g., Biomica for human microbiome, Lavie Bio for agriculture, AgPlenus for crop protection) allows Evogene to address multiple large and distinct markets, diversifying risk and expanding potential revenue streams.

Product Development Uncertainty: Evogene's success is highly dependent on its ability to successfully develop, test, and commercialize new products and technologies, which is a long, costly, and uncertain process with no guarantee of market success.

Regulatory Approval Hurdles: Many of Evogene's potential products or technologies in agri-food, health, and industrial biotech fields require extensive and costly regulatory approvals, which can be delayed, denied, or subject to changes in requirements.

Intellectual Property Protection Concerns: Evogene relies heavily on its proprietary computational biology platform and resulting intellectual property; the inability to obtain, maintain, defend, and enforce its patents and other IP rights could severely impact its competitive position.